- Home
- NVS vs WELL Comparison
NVS vs WELL Comparison
Compare NVS & WELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVS | WELL |
|---|---|---|
| Founded | 1895 | 1970 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.9B | 170.7B |
| IPO Year | 2001 | 1994 |
Fundamental Metrics
Financial Performance| Metric | NVS | WELL |
|---|---|---|
| Price | $152.66 | $229.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $144.00 | ★ $224.38 |
| AVG Volume (30 Days) | 1.6M | ★ 2.7M |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.16% | 1.40% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.02 |
| Revenue | N/A | ★ $10,838,034,000.00 |
| Revenue This Year | $2.30 | $28.56 |
| Revenue Next Year | $5.27 | $6.97 |
| P/E Ratio | ★ $23.13 | $221.60 |
| Revenue Growth | N/A | ★ 35.63 |
| 52 Week Low | $120.78 | $161.26 |
| 52 Week High | $170.46 | $255.20 |
Technical Indicators
Market Signals| Indicator | NVS | WELL |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 39.52 |
| Support Level | $149.41 | $196.35 |
| Resistance Level | $153.63 | $239.11 |
| Average True Range (ATR) | 2.01 | 5.76 |
| MACD | -0.37 | -2.39 |
| Stochastic Oscillator | 3.11 | 3.41 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
About WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,800 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 900 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.